Trial Profile
A two-centre, randomised, double-blind, double-dummy, placebo-controlled, 3-period cross-over study to evaluate the effect of treatment with repeat doses of GW274150 on the allergen-induced late asthmatic response in subjects with mild asthma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Aug 2023
Price :
$35
*
At a glance
- Drugs GW 274150 (Primary) ; Montelukast
- Indications Asthma
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 24 Mar 2009 Actual initiation date changed from Jan 2005 to Nov 2004; trial phase changed from II to I as reported by ClinicalTrials.gov.
- 09 Mar 2008 Status change
- 05 Sep 2006 New trial record.